Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Avalo Therapeutics (AVTX) Raw Materials (2018)

Avalo Therapeutics filings provide 1 years of Raw Materials readings, the most recent being $11392.0 for Q4 2018.

On a quarterly basis, Raw Materials changed N/A to $11392.0 in Q4 2018 year-over-year; TTM through Dec 2018 was $11392.0, a N/A change, with the full-year FY2018 number at $11392.0, changed N/A from a year prior.
Raw Materials hit $11392.0 in Q4 2018 for Avalo Therapeutics.
In the past five years, Raw Materials ranged from a high of $11392.0 in Q4 2018 to a low of $11392.0 in Q4 2018.